McKesson Corporation $MCK is Walter Public Investments Inc.’s 7th Largest Position

Walter Public Investments Inc. boosted its position in shares of McKesson Corporation (NYSE:MCK) by 118.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,387 shares of the company’s stock after purchasing an additional 9,417 shares during the period. McKesson comprises 3.6% of Walter Public Investments Inc.’s holdings, making the stock its 7th biggest holding. Walter Public Investments Inc.’s holdings in McKesson were worth $15,046,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Walkner Condon Financial Advisors LLC grew its stake in shares of McKesson by 13.0% during the first quarter. Walkner Condon Financial Advisors LLC now owns 610 shares of the company’s stock valued at $528,000 after buying an additional 70 shares during the last quarter. Kepler Cheuvreux Suisse SA purchased a new stake in shares of McKesson in the first quarter worth approximately $2,219,000. Northstar Group Inc. bought a new stake in shares of McKesson during the 1st quarter worth approximately $208,000. Koshinski Asset Management Inc. lifted its stake in shares of McKesson by 10.8% during the 1st quarter. Koshinski Asset Management Inc. now owns 2,755 shares of the company’s stock worth $2,384,000 after acquiring an additional 268 shares during the last quarter. Finally, QRG Capital Management Inc. boosted its holdings in McKesson by 35.9% during the 1st quarter. QRG Capital Management Inc. now owns 9,924 shares of the company’s stock valued at $8,588,000 after acquiring an additional 2,619 shares during the period. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Stock Down 0.0%

MCK opened at $786.17 on Friday. The stock’s fifty day moving average is $769.23 and its two-hundred day moving average is $838.98. The company has a market capitalization of $92.05 billion, a P/E ratio of 20.44, a PEG ratio of 1.29 and a beta of 0.31. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00.

McKesson (NYSE:MCK) last issued its earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business had revenue of $96.30 billion during the quarter, compared to analysts’ expectations of $101.35 billion. During the same period in the prior year, the business earned $10.12 EPS. The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities analysts anticipate that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 1st. Investors of record on Monday, June 1st were paid a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is 8.53%.

Analysts Set New Price Targets

Several brokerages have commented on MCK. Citigroup cut their price objective on McKesson from $975.00 to $945.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. JPMorgan Chase & Co. lowered their target price on shares of McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $875.00 price target on shares of McKesson in a report on Friday, May 8th. Barclays reduced their price target on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Finally, UBS Group lifted their price objective on shares of McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Friday, May 8th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $960.53.

Insider Buying and Selling at McKesson

In other news, EVP Michele Lau sold 3,550 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $2,701,869.50. Following the completion of the sale, the executive vice president owned 3,247 shares in the company, valued at approximately $2,471,259.23. The trade was a 52.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $764.00, for a total transaction of $101,612.00. Following the completion of the sale, the chief accounting officer directly owned 632 shares of the company’s stock, valued at $482,848. The trade was a 17.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 20,285 shares of company stock valued at $15,546,137 in the last 90 days. Insiders own 0.06% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.